Reported 8 months ago
On June 16, 2024, in Taipei, the regenerative medicine sector sees a significant boost, with companies like Taiwan Bio, YongSheng Bio, XJ Cell, and Kyushu Bio advancing in clinical trials for new drugs. Alongside developing an exosome drug platform, Chang Sheng is also constructing its fourth clinical-grade GMP regenerative medicine factory. Taiwan Bio's Chondrochymal for degenerative joint diseases progresses to Phase III clinical trials, aiming to complete by the first quarter of 2028. YongSheng receives FDA approval for a unique umbilical cord blood cell treatment for acute ischemic strokes, marking a breakthrough in clinical trials. These developments, along with partnerships and expansions, signify a significant growth in the regenerative medicine industry.
Source: YAHOO